TOPICS

Category: Psoriasis

Pipeline Perspectives and Therapy Updates: Dual Inhibition of IL-17 Cytokines and Expanding the Therapeutic Reach of Dupilumab

J Clin Aesthet Dermatol. 2020;13(11):32–34 by James Q. Del Rosso, DO, FAAD, FAOCD Dr. Del Rosso is Research Director at JDR Dermatology Research in Las Vegas, Nevada, is with Thomas Dermatology in Las Vegas, Nevada, and is an adjunct clinical professor of dermatology at Touro University Nevada in Henderson, Nevada. FUNDING: No funding was provided

CONTINUE READING »

Innovations in Psoriasis Management: Based on Selected Presentations from Symposium for Cosmetic Advances & Laser Education (SCALE) 2020 Virtual Congress

J Clin Aesthet Dermatol 2020;13(11 Suppl 2):S8–S23 Innovations in Psoriasis Management Based on Selected Presentations from Symposium for Cosmetic Advances & Laser Education (SCALE) 2020 Virtual Congress July 24—26, 2020, Nashville, Tennessee.   by Jo Ann LeQuang Owner, LeQ Medical, Angleton, Texas; Director of Scientific Communications, NEMA Research, Inc., Naples, Florida; Founding Director, No Baby

CONTINUE READING »

Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Long-term Clinical Study

J Clin Aesthet Dermatol. 2020;13(10):18–22 by Luis Puig, MD, PhD; Baojin Zhu, PhD; Russel Burge, PhD, MA; David Shrom, PhD; Yan Dong, PhD; Wei Shen, PhD; Lotus Mallbris, MD, PhD; and Kristian Reich, PhD Dr. Puig is with Hospital de la Santa Creu i Sant Pau and Universitat Autonoma de Barcelona in Spain. Drs. Zhu,

CONTINUE READING »